Kopran Limited KOPRAN.NS · Stock Open Kopran Limited in new tab
Kopran Limited Analysis (KOPRAN.NS)
Is Kopran Limited a good investment? Kopran Limited (KOPRAN.NS) is currently trading at 282.05 INR.
In terms of valuation, the stock trades at a P/E ratio of 56.16. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Kopran Limited is expected to release its next earnings report on May 13, 2026. The market consensus estimate for Forward EPS is 5.67.
For income investors, Kopran Limited pays a dividend yield of 1.08%. With a payout ratio of 58%, the dividend appears sustainable.
Investor FAQ
Does Kopran Limited pay a dividend?
Yes, it pays an annual dividend of 3.00 INR (1.08% yield).
What asset class is Kopran Limited?
Kopran Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be May 13, 2026. The company currently has a trailing EPS of 5.18.
Company Profile
Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, penicillin, quinolone, anti-protozoal, sulphonamides, respiratory, tetracycline, cardiovascular, anti-diabetic, urology, pain management and anti-inflammatory, gastrointestinal, erectile dysfunction, anthemintic, anti-allergic, central nervous system, anti-malarial, anti-thyroid, and carbapenems. In addition, the company offers drugs for anti-hypertensive, neuromodulator, anti-acne, anti-infective, antibiotic, anti-thrombotic, anti-diabetic, anti-asthamatic, antihyperlipidemic, anti-convulsants, anti-anxiety, pulmonary arterial hypertension, chronic heart failure, neuropathic pain, and erosive esophagitis. Kopran Limited was incorporated in 1958 and is based in Mumbai, India.
| Year | Total Dividends |
|---|---|
| ▸2027 |
6.00 INR
|
| Sept. 17, 2027 (estimated) | 6.0000 |
| ▸2026 |
6.00 INR
|
| Oct. 12, 2026 (estimated) | 3.0000 |
| Sept. 17, 2026 | 3.0000 |
| ▸2025 |
3.00 INR
|
| Oct. 11, 2025 | 3.0000 |
| ▸2024 |
3.00 INR
|
| Oct. 11, 2024 | 3.0000 |
| ▸2023 |
3.00 INR
|
| Oct. 14, 2023 | 3.0000 |
| ▸2022 |
3.00 INR
|
| Sept. 28, 2022 | 3.0000 |
| ▸2021 |
1.50 INR
|
| Sept. 30, 2021 | 1.5000 |
| ▸2020 |
1.50 INR
|
| Nov. 27, 2020 | 1.5000 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Kopran Limited | Sep 17, 2026 | Paid | 3.0 INR |
Community Discussion